Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: zoya who wrote (26158)	3/4/1999 3:29:00 PM
From: kendall harmon	Respond to of 120523

SNAP worth a look imo. An overreaction. Synaptic Pharmaceutical Migraine Program Update PARAMUS, N.J., March 4 /PRNewswire/ -- Synaptic Pharmaceutical Corporation (Nasdaq: SNAP - news) has been informed by Eli Lilly and Company that Lilly has temporarily delayed the beginning of Phase III clinical trials of the migraine compound (LY334370) identified as part of Synaptic's collaboration with Lilly. The reason for the delay, according to Lilly, is to enable Lilly to collect additional information that will help assess the safety and tolerability of the compound. Lilly is considering revisions to the clinical study protocols based on discussions with the FDA since the week of February 18, 1999. The Phase III clinical trials had been scheduled to commence in March. Migraine headache is a condition that involves periodic throbbing headaches often accompanied by nausea and vomiting. It is believed that the prevalence of migraine in the general population may be as high as 10 percent. Loss in work productivity provides an economic reason for improved therapies in this underserved market. The market for migraine therapies is estimated to be about $1.2 billion today and could grow to approximately $3 billion by the year 2000 because awareness of existing therapies will increase as new drugs enter the marketplace. LY334370 is a selective serotonin 1F agonist (SSOFRA), which represents a new class of potential treatments for migraine headache. Data from three Phase II clinical trials conducted by Lilly indicated that the compound is efficacious in the treatment of migraine without the cardiovascular side effects associated with other treatments currently on the market. Synaptic Pharmaceutical Corporation has developed ''human receptor-targeted drug design technology,'' in which cloned human receptors are used as targets for the design of potential drugs. The Company is engaged in collaborations with two pharmaceutical companies in addition to Lilly.